Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Impact of a pregabalin step therapy policy among medicare advantage beneficiaries.

Suehs BT, Louder A, Udall M, Cappelleri JC, Joshi AV, Patel NC.

Pain Pract. 2014 Jun;14(5):419-26. doi: 10.1111/papr.12073. Epub 2013 May 23.

PMID:
23701733
2.

Impact of a step-therapy protocol for pregabalin on healthcare utilization and expenditures in a commercial population.

Udall M, Louder A, Suehs BT, Cappelleri JC, Joshi AV, Patel NC.

J Med Econ. 2013;16(6):784-92. doi: 10.3111/13696998.2013.793692. Epub 2013 Apr 26.

PMID:
23565813
3.

Healthcare utilization and cost effects of prior authorization for pregabalin in commercial health plans.

Margolis JM, Cao Z, Onukwugha E, Sanchez RJ, Alvir J, Joshi AV, Mullins CD.

Am J Manag Care. 2010 Jun;16(6):447-56.

4.

Costs of pregabalin or gabapentin for painful diabetic peripheral neuropathy.

Udall M, Harnett J, Mardekian J.

J Med Econ. 2012;15(2):361-70. doi: 10.3111/13696998.2011.650773. Epub 2012 Jan 9.

PMID:
22181052
5.

Effects of a Medicaid prior authorization policy for pregabalin.

Margolis JM, Johnston SS, Chu BC, Onukwugha E, Hvidsten K, Alvir J, Rossi JG, Mullins CD.

Am J Manag Care. 2009 Oct 1;15(10):e95-102.

6.

Comparing healthcare costs of Medicaid patients with postherpetic neuralgia (PHN) treated with lidocaine patch 5% versus gabapentin or pregabalin.

Kirson NY, Ivanova JI, Birnbaum HG, Wei R, Kantor E, Puenpatom RA, Ben-Joseph RH, Summers KH.

J Med Econ. 2010;13(3):482-91. doi: 10.3111/13696998.2010.506176.

PMID:
20684669
7.

Health care costs in patients with painful diabetic peripheral neuropathy prescribed pregabalin or duloxetine.

Burke JP, Sanchez RJ, Joshi AV, Cappelleri JC, Kulakodlu M, Halpern R.

Pain Pract. 2012 Mar;12(3):209-18. doi: 10.1111/j.1533-2500.2011.00478.x. Epub 2011 Jun 16.

PMID:
21676163
8.

Evaluation of healthcare resource utilization and costs in employees with pain associated with diabetic peripheral neuropathy treated with pregabalin or duloxetine.

Margolis J, Cao Z, Fowler R, Harnett J, Sanchez RJ, Mardekian J, Silverman SL.

J Med Econ. 2010;13(4):738-47. doi: 10.3111/13696998.2010.535878. Epub 2010 Nov 24.

PMID:
21091395
9.

Retrospective evaluation of clinical characteristics, pharmacotherapy and healthcare resource use among patients prescribed pregabalin or duloxetine for diabetic peripheral neuropathy in usual care.

Gore M, Zlateva G, Tai KS, Chandran AB, Leslie D.

Pain Pract. 2011 Mar-Apr;11(2):167-79. doi: 10.1111/j.1533-2500.2010.00415.x. Epub 2010 Aug 17.

PMID:
20723096
10.

Characteristics, treatment, and health care expenditures of Medicare supplemental-insured patients with painful diabetic peripheral neuropathy, post-herpetic neuralgia, or fibromyalgia.

Johnston SS, Udall M, Alvir J, McMorrow D, Fowler R, Mullins D.

Pain Med. 2014 Apr;15(4):562-76. doi: 10.1111/pme.12328. Epub 2014 Jan 16.

PMID:
24433487
11.

Clinical comorbidities, treatment patterns, and healthcare costs among patients with fibromyalgia newly prescribed pregabalin or duloxetine in usual care.

Gore M, Tai KS, Chandran A, Zlateva G, Leslie D.

J Med Econ. 2012;15(1):19-31. doi: 10.3111/13696998.2011.629262. Epub 2011 Oct 20.

PMID:
21970699
12.

A retrospective, matched cohort study of potential drug-drug interaction prevalence and opioid utilization in a diabetic peripheral neuropathy population initiated on pregabalin or duloxetine.

Ellis JJ, Sadosky AB, Ten Eyck LL, Mudumby P, Cappelleri JC, Ndehi L, Suehs BT, Parsons B.

BMC Health Serv Res. 2015 Apr 15;15:159. doi: 10.1186/s12913-015-0829-9.

13.

Clinical characteristics, pharmacotherapy, and healthcare resource use among patients with diabetic neuropathy newly prescribed pregabalin or gabapentin.

Gore M, Tai KS, Zlateva G, Bala Chandran A, Leslie D.

Pain Pract. 2011 Nov-Dec;11(6):528-39. doi: 10.1111/j.1533-2500.2011.00450.x. Epub 2011 Mar 16.

PMID:
21435162
14.

Identification of patients with painful diabetic peripheral neuropathy who have a favorable cost profile with pregabalin treatment.

Udall M, Mardekian J, Cabrera J.

Pain Pract. 2013 Jul;13(6):476-84. doi: 10.1111/papr.12008. Epub 2012 Nov 14.

PMID:
23150918
15.

Adding pregabalin or gabapentin for the management of community-treated patients with painful diabetic peripheral neuropathy: a comparative cost analysis.

Sicras A, Rejas J, Navarro R, Planas A.

Clin Drug Investig. 2013 Nov;33(11):825-35. doi: 10.1007/s40261-013-0131-8.

PMID:
24085589
16.
17.

Real-world evaluation of health-care resource utilization and costs in employees with fibromyalgia treated with pregabalin or duloxetine.

Harnett J, Margolis J, Cao Z, Fowler R, Sanchez RJ, Mardekian J, Silverman SL.

Pain Pract. 2011 May-Jun;11(3):217-29. doi: 10.1111/j.1533-2500.2010.00440.x. Epub 2010 Dec 28.

PMID:
21199319
18.

Prior authorization in the treatment of patients with pDPN and FM.

Placzek HE, Masters ET, Gu T, Cappelleri JC, Wasser TE, Clair AG, Cook JP, Eisenberg DF.

Pain Pract. 2015 Jan;15(1):E9-19. doi: 10.1111/papr.12258. Epub 2014 Nov 11.

PMID:
25387598
19.

Clinical characteristics, pharmacotherapy and healthcare resource use among patients with fibromyalgia newly prescribed gabapentin or pregabalin.

Gore M, Sadosky AB, Zlateva G, Clauw DJ.

Pain Pract. 2009 Sep-Oct;9(5):363-74. doi: 10.1111/j.1533-2500.2009.00292.x. Epub 2009 Jun 4.

20.

Supplemental Content

Support Center